title: Is the battle over bevacizumab coverage looming?
authors.affiliation: Bloomberg News in Washington, DC, USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Larkin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D017277:Drug Approval; D005260:Female; D006801:Humans; D007348:Insurance, Health; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab